Meeting
2023 ASCO Annual Meeting
Assessment of sociodemographic disparities in outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE.
Authors
Stephen V. Liu
Georgetown University, Washington, DC
Stephen V. Liu , Rachel Salomonsen , Ryan Tattersfield , Alice Wang , Ling Cai , Sam Sadow , Solange Peters
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9055)
DOI
10.1200/JCO.2023.41.16_suppl.9055
Abstract #
9055
Poster Bd #
43
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
First Author: Justine Yang Bruce
Poster
2018 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
First Author: Andreas Nicholas Saltos
Poster
2017 ASCO Annual Meeting
Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.
First Author: Luis G. Paz-Ares
Poster
2017 ASCO Annual Meeting
A phase I study of enadenotucirev (EnAd), an oncolytic Ad11/Ad3 chimeric group B adenovirus, in combination with nivolumab in tumors of epithelial origin.
First Author: Wael A. Harb